A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in
patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.